Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: David Klatzmann, MD, PhD
Woman and Man Max 99 years
David Klatzmann, MD, PhD
Update Il y a 4 ans
ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy and safety of ILT-101 (human recombinant interleukin 2 (IL-2)) in patients with moderate to severe systemic lupus erythematosus.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Klatzmann, MD, PhD
Update Il y a 4 ans
Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes
Human recombinant interleukin-2 (rhIL-2) is a biological signalling protein playing a key role in the regulation of the immune system. At high doses, rhIL-2 activates the immune effectors ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
David Klatzmann, MD, PhD
Update Il y a 4 ans
T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study
T regulatory lymphocytes were shown to be partly responsible for immune tolerance to cancer cells. In that respect these cells oppose to the mounting of an efficacious immune response need...
Country
None
organs
None
Specialty
None
Closed trial
More information